These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35004781)

  • 21. Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis: A Population-Based Cohort Study.
    Tran T; Assayag D; Ernst P; Suissa S
    Chest; 2021 Feb; 159(2):673-682. PubMed ID: 32882251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health Care Costs at the End of Life for Patients with Idiopathic Pulmonary Fibrosis. Evaluation of a Pilot Multidisciplinary Collaborative Interstitial Lung Disease Clinic.
    Kalluri M; Lu-Song J; Younus S; Nabipoor M; Richman-Eisenstat J; Ohinmaa A; Bakal JA
    Ann Am Thorac Soc; 2020 Jun; 17(6):706-713. PubMed ID: 32197048
    [No Abstract]   [Full Text] [Related]  

  • 23. Characteristics of lung cancer in idiopathic pulmonary fibrosis with single lung transplant versus non-transplanted patients: a retrospective observational study.
    Gershman E; Zer A; Pertzov B; Shtraichman O; Shitenberg D; Heching M; Rosengarten D; Kramer M
    BMJ Open Respir Res; 2020 Jun; 7(1):. PubMed ID: 32565443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data.
    Mortimer K; Hartmann N; Chan C; Norman H; Wallace L; Enger C
    BMC Pulm Med; 2019 Jan; 19(1):11. PubMed ID: 30630460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.
    Delanote I; Wuyts WA; Yserbyt J; Verbeken EK; Verleden GM; Vos R
    BMC Pulm Med; 2016 Nov; 16(1):156. PubMed ID: 27863518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment.
    Biondini D; Cocconcelli E; Bernardinello N; Lorenzoni G; Rigobello C; Lococo S; Castelli G; Baraldo S; Cosio MG; Gregori D; Saetta M; Balestro E; Spagnolo P
    Respir Res; 2021 Apr; 22(1):98. PubMed ID: 33794872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry.
    Salisbury ML; Conoscenti CS; Culver DA; Yow E; Neely ML; Bender S; Hartmann N; Palmer SM; Leonard TB;
    Ann Am Thorac Soc; 2020 Nov; 17(11):1413-1423. PubMed ID: 32574517
    [No Abstract]   [Full Text] [Related]  

  • 28. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.
    Fan Y; Bender SD; Conoscenti CS; Davidson-Ray L; Cowper PA; Palmer SM; de Andrade JA;
    Chest; 2020 Jun; 157(6):1522-1530. PubMed ID: 32004554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis.
    Kang J; Han M; Song JW
    Sci Rep; 2020 Sep; 10(1):15620. PubMed ID: 32973215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study.
    Brown AW; Fischer CP; Shlobin OA; Buhr RG; Ahmad S; Weir NA; Nathan SD
    Chest; 2015 Jan; 147(1):173-179. PubMed ID: 25188694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
    Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
    Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.
    Case AH; Hellkamp AS; Neely ML; Bender S; Dilling DF; Gulati M; Hotchkin DL; Huie TJ; Lancaster L; Snyder LD; Conoscenti CS; Palmer SM
    Ann Am Thorac Soc; 2020 Jun; 17(6):699-705. PubMed ID: 32040340
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
    Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
    Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hospital cost and length of stay in idiopathic pulmonary fibrosis.
    Mooney JJ; Raimundo K; Chang E; Broder MS
    J Med Econ; 2017 May; 20(5):518-524. PubMed ID: 28092235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE.
    Kolonics-Farkas AM; Šterclová M; Mogulkoc N; Kus J; Hájková M; Müller V; Jovanovic D; Tekavec-Trkanjec J; Littnerová S; Hejduk K; Vašáková M
    Drug Saf; 2020 Oct; 43(10):971-980. PubMed ID: 32734423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.
    Poletti V; Vancheri C; Albera C; Harari S; Pesci A; Metella RR; Campolo B; Crespi G; Rizzoli S;
    Respir Res; 2021 Feb; 22(1):66. PubMed ID: 33627105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplantation Outcome.
    Dotan Y; Vaidy A; Shapiro WB; Zhao H; Dass C; Toyoda Y; Marchetti N; Shenoy K; Cordova FC; Criner GJ; Mamary AJ
    Chest; 2018 Oct; 154(4):818-826. PubMed ID: 29966665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
    Dempsey TM; Sangaralingham LR; Yao X; Sanghavi D; Shah ND; Limper AH
    Am J Respir Crit Care Med; 2019 Jul; 200(2):168-174. PubMed ID: 31150266
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.